三生制药“二连售":1.5亿美元再售PD-1/VEGF国内权益

Ofweek维科网
Jul 25, 2025

当三生制药用1.5亿卖掉国内权益时,它忘记了一点:资本市场从不为“现金”鼓掌,只为“梦想”买单。7月24日,三生制药宣布,与辉瑞就PD-1/VEGF双抗SSGJ-707达成的全球授权协议于今日正式生效。此次交易堪称国产创新药“出海”里程碑,交易总额高达60.5亿美元,其中首付款高达12.5亿美元,创下中国创新药首付款纪录。更值得注意的是,辉瑞追加1.5亿美元获得SSGJ-707在中国内地的独家...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10